Core Viewpoint - Alvotech has successfully completed the acquisition of Xbrane Biopharma's R&D organization and a biosimilar candidate to Cimzia®, enhancing its development capacity and presence in the Swedish life science sector [1][2]. Group 1: Transaction Details - The acquisition was announced on March 20, 2025, and approved on April 14, 2025, with a total purchase price of approximately SEK 275 million (US$28.9 million) [2]. - The payment structure includes a cash payment of approximately SEK 102.2 million, assumption of convertible debt of approximately SEK 152.75 million, and assumption of accounts payable related to the biosimilar candidate of approximately SEK 20 million [7]. Group 2: Company Overview - Alvotech is a biotech company focused on developing and manufacturing biosimilar medicines, aiming to be a global leader in the biosimilar space with a fully integrated approach and broad in-house capabilities [4]. - The company has two approved biosimilars, targeting Humira® (adalimumab) and Stelara® (ustekinumab), and a pipeline of nine disclosed biosimilar candidates for various diseases [4]. - Alvotech has established strategic commercial partnerships across multiple regions, including the United States, Europe, Japan, China, and parts of South America, Africa, and the Middle East [4].